Search
for
Sort by
Research 151–180 of 1000+
- The effect of Cotinus coggygria L. ethanol extract in the treatment of burn wounds
- Indirect skin sign of COVID‐19 days: Striae rubrae
- Reflections of COVID-19 Pandemic on Dermatology Outpatient Clinics
- Gold nanoparticle/silk fibroin-based nanofiber enhances skin regeneration
- Ovarian Hilus Cell Hyperplasia and Sertoli-Leydig Cell Tumor in a Patient with Postmenopausal Virilization: a Rare Case Report
- SAÇ DÖKÜLMESİ: LABORATUAR İNCELEMELERİ KİME GEREKLİ?
- A preliminary observation: Male pattern hair loss among hospitalized COVID‐19 patients in Spain – A potential clue to the role of androgens in COVID‐19 severity
- Androgen sensitivity gateway to COVID‐19 disease severity
- Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”
- Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31
- <i>Sept4/</i> ARTS Regulates Stem Cell Apoptosis and Skin Regeneration
- Racial variations in COVID‐19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti‐androgens a potential treatment for COVID‐19?
- Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men
- What does androgenetic alopecia have to do with COVID‐19? An insight into a potential new therapy
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Clinical utility and validity of minoxidil response testing in androgenetic alopecia
- Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
- Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
- Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical)
- Alopecia Universalis Successfully Treated With Adalimumab
- 5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia
- Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19
- Time of onset and duration of post-COVID-19 acute telogen effluvium
- Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign
- Radiofrequency treatment induces fibroblast growth factor 2 expression and subsequently promotes neocollagenesis and neoangiogenesis in the skin tissue
- Clinical symptoms of hyperandrogenic women diagnosed with COVID‐19
- Platelet-rich plasma as a novel treatment for lichen planopillaris
- Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia
- Biphasic Regulation of HMG-CoA Reductase Expression and Activity during Wound Healing and Its Functional Role in the Control of Keratinocyte Angiogenic and Proliferative Responses
- Roles of existing drug and drug targets for COVID-19 management